Article Text

Download PDFPDF
Randomised controlled trial
Valsartan is more effective than placebo in reducing the incidence of diabetes in people with impaired glucose tolerance and cardiovascular disease or risk factors but has no effect on cardiovascular outcomes
  1. Yves Lacourcière1,
  2. Luc Poirier1
  1. 1Hypertension Unit, Centre Hospitalier Universitaire de Québec, Quebec, Canada
  1. Correspondence to Yves Lacourcière
    2705 Laurier Boulevard, Quebec, QC G1V 4G2, Canada; yves.lacourciere{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Impaired glucose tolerance, which represents an intermediate stage before the onset of diabetes, is associated with an increased risk of cardiovascular diseases. Moreover, the concomitant presence of confirmed cardiovascular disease or cardiovascular risk factors in glucose-intolerant patients significantly augments their risk of cardiovascular events. Among the different treatment strategies used in high-risk patients, blockade of the renin-angiotensin system (RAS) has been shown to decrease the onset of new diabetes as well as the incidence of cardiovascular events. Therefore, the NAVIGATOR study was designed to evaluate the efficacy of blocking the RAS on the incidence of predetermined cardiovascular events such as myocardial infarction and stroke and on the prevalence of new diabetes.


This was a double-blind, randomised, placebo-controlled, clinical trial ( …

View Full Text


  • Competing interests None.